natgillin/translations-raw huggingface dataset:
Anal intraepitelial neoplasi (AIN) grad 2/3 (moderat til high-grade dysplasi) blev anvendt som surrogatmarkør for analcancer i de kliniske studier.
Anal Intraepithelial Neoplasia (AIN) Grade 2/3 (moderate to high-grade dysplasia) was used in the clinical trials as a surrogate marker for anal cancer.
Hertil kommer, at der i kliniske studier er observeret bivirkninger med en hyppighed på under 1 %, som af investigatorerne blev bedømt som værende vaccine- eller placeborelaterede:
In addition, in clinical trials adverse reactions that were judged to be vaccine- or placebo-related by the study investigator were observed at frequencies lower than 1%:
Overfølsomhed over for de aktive stoffer eller over for et eller flere af hjælpestofferne anført i pkt.
Hypersensitivity to the active substances or to any of the excipients.
På injektionsstedet: hæmatom, pruritus Asteni*, kulderystelser*, træthed*, utilpashed*
At the injection site: hematoma, pruritus Not known Asthenia*, chills*, fatigue*, malaise*
I post hoc analyser af personer (der fik mindst én vaccination) med tegn på tidligere HPV-infektion med en af vaccinetyperne (seropositiv), men som ikke længere var detekterbar (PCR-negativ) på starttidspunkt for vaccination) var Silgards forebyggende effekt over for recidiv forårsaget af den samme HPV type 100 % (95 % CI: 62,8; 100,0; 0 versus 12 tilfælde [n = 2.572 i poolede studier med unge kvinder]) mod HPV 6-, 11-, 16- og 18 relateret CIN 2/3, VIN 2/3, VaIN 2/3 og kondylomer hos kvinder 16-26 år.
In post hoc analyses of individuals (who received at least one vaccination) with evidence of a prior infection with a vaccine HPV type (seropositive) no longer detectable (PCR negative) at vaccination onset, the efficacy of Silgard to prevent conditions due to the recurrence of the same HPV type was 100% (95% CI: 62.8, 100.0; 0 vs. 12 cases [n = 2572 from pooled studies in young women]) against HPV 6-, 11-, 16-, and 18-related CIN 2/3, VIN 2/3, VaIN 2/3, and genital warts in women 16 to 26 years.
Effekt*** ved studiets afslutning (95 % CI)
Efficacy*** at end of study (95% CI)
0,5 ml suspension i et hætteglas (glas) med prop (FluroTec-belagt eller Teflon-belagt chlorbutylelastomer) og aftagelig plasthætte (aluminium krympebånd) i en pakkestørrelse på 1, 10 eller
0.5 ml suspension in a vial (glass) with stopper (FluroTec-coated or Teflon-coated chlorobutyl elastomer) and flip-off plastic cap (aluminium crimp band) in a pack size of 1, 10 or 20.
• effekten af Silgard imod HPV 6-, 11-, 16-, 18-relateret VIN2/3 og VaIN 2/3 henholdsvis 100 %
• the efficacy of Silgard against HPV 6-, 11-, 16-, 18-related VIN2/3 and VaIN 2/3 was 100%
(resultater ved
(end of study results)
Effekt hos mænd, der er naive over for de relevante vaccine-HPV-typer
Efficacy in Men naïve to the relevant vaccine HPV types
Silgard kan derfor bruges under amning.
Therefore Silgard can be used during breast-feeding.
L1 protein i form af viruslignende partikler produceret i gærceller (Saccharomyces cerevisiae CANADE 3C-5 (stamme 1895)) ved hjælp af rekombinant DNA-teknologi.
L1 protein in the form of virus-like particles produced in yeast cells (Saccharomyces cerevisiae CANADE 3C-5 (Strain 1895)) by recombinant DNA technology.
Hos personer, som allerede er inficeret med en eller flere af de HPV-typer, der indgår i vaccinen, kan Silgard dog stadig forebygge sygdomme, som skyldes de andre HPV-typer, som vaccinen beskytter imod.
However, in individuals who are already infected with one or more of the vaccine HPV types, Silgard can still protect against diseases associated with
Det andet tilfælde af CIN 3 blev observeret hos en patient, der var inficeret med HPV 51 på dag 1 (i 2 ud af 9 prøver); HPV 16 blev detekteret i en biopsi foretaget ved måned 51 (i 1 ud af 9 prøver), og HPV 56 blev detekteret i 3 ud af 9 prøver i væv, der blev udtaget under LEEP ved måned 52.
In the second CIN 3 case observed in a patient infected with HPV 51 at Day 1 (in 2 of 9 specimens); HPV 16 was detected at a Month 51 biopsy (in 1 of 9 specimens) and HPV 56 was detected in 3 of 9 specimens at Month 52 in tissue excised during LEEP. ***Patients were followed for up to 4 years (median 3.6 years) Note: Point estimates and confidence intervals are adjusted for person-time of follow-up.
0,5 ml suspension i en fyldt injektionssprøjte (glas) med stempelstopper (silikonebehandlet FluroTec-belagt brombutylelastomer eller ikke-belagt chlorbutylelastomer) og hætte (brombutyl) uden kanyle eller med en eller to kanyler - pakkestørrelse på 1, 10 eller 20.
0.5 ml suspension in a pre-filled syringe (glass) with plunger stopper (siliconized FluroTec-coated bromobutyl elastomer or non-coated chlorobutyl elastomer) and a tip cap (bromobutyl) without needle or with one or two needle(s) - pack size of 1, 10 or 20.
HPV 16 og HPV 18 antages at være ansvarlige for cirka 70 % af tilfældene af cancer i livmoderhalsen og 75-80 % af analcancertilfælde, 80 % af tilfældene af adenocarcinoma in situ (AIS), 45-70 % af tilfældene af high-grade cervikal intraepitelial neoplasi (CIN 2/3), 25 % af tilfældene af low-grade cervikal intraepitelial neoplasi (CIN 1), cirka 70 % af tilfældene af HPV-relaterede high-grade intraepiteliale neoplasier i vulva (VIN 2/3) og intraepiteliale neoplasier i vagina (VaIN 2/3) og 80 % af HPV relateret high-grade anal (AIN 2/3) intraepiteliale neoplasier.
HPV 16 and HPV 18 are estimated to be responsible for approximately 70% of cervical cancers and 75-80% of anal cancers; 80% of adenocarcinoma in situ (AIS); 45-70% of high-grade cervical intraepithelial neoplasia (CIN 2/3); 25% of low grade cervical intraepithelial neoplasia (CIN 1); approximately 70% of HPV related high-grade vulvar (VIN 2/3) and vaginal (VaIN 2/3) intraepithelial neoplasia and 80% of HPV related high-grade anal (AIN 2/3) intraepithelial neoplasia.
Brug af anden medicin eller vacciner sammen med Silgard Silgard kan gives samtidig med en Hepatitis B-vaccine eller med en kombineret boostervaccine indeholdende difteri (d) og tetanus (T) med enten pertussis (kighoste) [acellulær komponent] (aP) og/eller poliomyelitis [inaktiveret] (IPV) (TdaP, Td-IPV, TdaP-IPV vacciner) på et separat injektionssted (et andet sted på kroppen, f.eks. den anden arm eller det andet ben) under samme besøg.
Silgard can be given with a Hepatitis B vaccine or with a combined booster vaccine containing diphtheria (d) and tetanus (T) with either pertussis [acellular, component] (ap) and/or poliomyelitis [inactivated] (IPV) (dTap, dT-IPV, dTap-IPV vaccines) at a separate injection site (another part of your body, e.g. the other arm or leg) during the same visit.
Anti-HPV-responser ved måned 7 blandt 9 til 15 år gamle piger var ikke mindre end anti-HPVresponser i 16 til 26 år gamle kvinder, for hvem effekten var blevet bestemt i fase III-studierne.
Anti-HPV responses at Month 7 among 9- to 15-year-old girls were non-inferior to anti-HPV responses in 16- to 26-year-old women for whom efficacy was established in the phase III studies.
Silgard leveres i pakker med 1, 10 eller 20 fyldte sprøjter.
Silgard is available in packs of 1, 10 or 20 pre-filled syringes.
Silgard leveres i pakker med 1, 10 eller 20 hætteglas.
Silgard is available in packs of 1, 10 or 20 vials.
Indehaveren af markedsføringstilladelsen og fremstiller.
Marketing Authorisation Holder and Manufacturer
HPV 16- eller HPV 18
HPV 16- or HPV 18related CIN
I alle populationer (kvinder i alderen 9-45 år, mænd i alderen 9-26) blev de højeste GMT'er (cLIA) af anti-HPV 6, anti-HPV 11, anti-HPV 16 og anti-HPV 18 observeret i måned 7.
In all populations (women 9 - 45 years, men 9 - 26 years), peak anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 GMTs cLIA were observed at Month 7.
I den HPV-naive population (naive over for 14 almindeligt forekommende HPV-typer) reducerede Silgard andelen af mænd, der fik foretaget en biopsi, med 54,2 % (95 % CI: 28,3; 71,4), og andelen, som fik behandling, med 47,7 % (95 % CI: 18,4; 67,1), ved slutningen af studiet.
In the HPV naïve population (naïve to 14 common HPV types), Silgard reduced the proportion of men who had a biopsy by 54.2% (95% CI: 28.3, 71.4) and who were treated by 47.7% (95% CI: 18.4, 67.1) at end of study.
% Effekt (95 % CI)
% Efficacy (95%CI)
Natriumchlorid, L-histidin, polysorbat 80, natriumborat og vand til injektionsvæsker.
Sodium chloride, L-histidine, polysorbate 80, sodium borate and water for injections.
Tabel 6: Immunogenicitetssammenligning mellem 9- til 15-årige piger og 16- til 26-årige kvinder (per-protokol-population) baseret på titre målt med cLIA
Table 6: Immunogenicity bridging between 9- to 15-year-old girls and 16- to 26-year-old women (perprotocol population) based on titres as measured by cLIA
Vælg den rigtige nål til intramuskulær (IM) administration afhængigt af din patients størrelse og vægt.
• Two needles of different lengths are provided in the pack, choose the appropriate needle to ensure an intramuscular (IM) administration depending on your patient's size and weight.
Effekt** Ved 2 år (95 % CI)
Efficacy** at 2 years (95% CI)
Effekten over for HPV 16/18-relateret CIN 2/3 eller AIS er baseret på data fra protokollerne 005 (kun HPV 16-relaterede effektmål), 007, 013 og 015.
The efficacy for HPV 16/18 related CIN 2/3 or AIS is based on data from protocols 005 (16-related endpoints only), 007, 013, and 015.
Efter grundigt omrystning, er den en hvid, uklar væske.
After thorough agitation, it is a white, cloudy liquid.
MINDSTEKRAV TIL MÆRKNING PÅ SMÅ INDRE EMBALLAGER MÆRKATTEKST TIL HÆTTEGLAS
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Pre-filled syringe label text
Hos mænd, som var naive over for 14 almindeligt forekommende HPV-typer, reducerede Silgard forekomsten af eksterne genitale læsioner forårsaget af vaccine- eller ikke-vaccine-HPV-typer med 81,5 % (95 % CI: 58,0;
Among men who were naïve to 14 common HPV types, administration of Silgard reduced the incidence of external genital lesions caused by vaccine- or non-vaccine HPV types by 81.5% (95% CI: 58.0, 93.0).
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE TEKST TIL YDERKARTONEN
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON TEXT
* Personerne i PPE-populationen fik alle 3 vaccinationer inden for 1 år efter rekruttering, havde ingen væsentlige afvigelser, og var naive over for de(n) relevante HPV-type(r) forud for første dosis og indtil 1 måned efter 3.
*The individuals in the PPE population received all 3 vaccinations within 1 year of enrolment, had no major protocol deviations, and were naïve to the relevant HPV type(s) prior to dose 1 and through 1 month Postdose 3
Personer på 14 år og derover Silgard bør indgives efter et program med 3 doser (0,5 ml ved måned 0, 2 og 6).
Individuals 14 years of age and older Silgard should be administered according to a 3-dose (0.5 ml at 0, 2, 6 months) schedule.
Tabel 7: Immunogenicitetssammenligning mellem 9-15-årige drenge og 16-26-årige mænd (perprotokol-population) baseret på titre målt med cLIA
Table 7: Immunogenicity bridging between 9- to 15-year-old boys and 16- to 26-year-old men (perprotocol population) based on titres as measured by cLIA
Natriumchlorid, L-histidin, polysorbat 80, natriumborat, vand til injektionsvæsker.
Sodium chloride, L-histidine, polysorbate 80, sodium borate, water for injections.
1 dosis Silgard injektionsvæske, suspension indeholder 0,5 ml.
What Silgard looks like and contents of the pack 1 dose of Silgard suspension for injection contains 0.5 ml.
HPV-typerne 16 og 18 er ansvarlige for cirka 70 % af tilfældene af livmoderhalskræft, 75-80 % af tilfældene af endetarmskræft, 70 % af HPV-relaterede forstadier til kræft i de ydre kønsorganer og skeden og 75 % af HPV relaterede forstadier til kræftlæsioner i endetarmen.
HPV types 16 and 18 are responsible for approximately 70% of cervical cancer cases, 75-80% of anal cancer cases; 70% of HPV-related pre-cancerous lesions of the vulva and vagina; 75% of HPV related pre-cancerous lesions of the anus.
Fuldt analysesæt inkluderede mænd uanset baseline-HPV-status på dag 1, som fik mindst 1 vaccination og hvor registrering af endepunkter påbegyndtes på dag 1.
The Full Analysis Set population included men regardless of baseline HPV status at Day 1, who received at least one vaccination and in whom case counting started at Day 1.
Den modificerede intention to treat (ITT) population inkluderede kvinder uanset baseline HPV-status på dag 1, der fik mindst en vaccination, og for hvem registrering af sygdomstilfælde påbegyndtes 1 måned efter administration af første dosis.
The modified intention to treat (ITT) population included women regardless of baseline HPV status at Day 1, who received at least one vaccination and in whom case counting started at 1 month Postdose 1.
Sjældne (forekommer hos mellem 1 og 10 ud af 10.000 patienter): Nældefeber (urticaria).
Rarely (less than 1 in 1000 patients): hives (urticaria).
Anti-HPV-niveauerne hos personer i placebogruppen, som havde overstået en HPV-infektion (seropositive og PCR-negative), var væsentligt lavere end dem, der induceredes af vaccinen.
Anti-HPV levels in placebo individuals who had cleared an HPV infection (seropositive and PCR
Fuldt analysesæt (også kaldt ITT-populationen) inkluderede kvinder uanset baseline HPV-status på dag 1, som fik mindst en vaccination, og hvor registrering af endepunkter påbegyndtes på dag 1.
The Full Analysis Set population (also known as the ITT population) included women regardless of baseline HPV status at Day 1, who received at least one vaccination and in whom case counting started at Day 1.
De kan finde yderligere oplysninger om Silgard på Det Europæiske Lægemiddelagenturs hjemmeside
Detailed information on this medicinal product is available on the website of the European Medicines
I den HPVnaive population (naive over for 14 almindeligt forekommende HPV-typer og med negativ Pap-test ved dag 1) reducerede Silgard antallet af kvinder, som fik foretaget en definitiv cervikal behandlingsprocedure (Loop Electro-Excision Procedure eller koldknivskonisering) med 41,9 % (95 % CI: 27,7; 53,5).
In the HPV naïve population (naïve to 14 common HPV types and had a negative Pap test at Day 1), Silgard reduced the proportion of women who experienced a definitive cervical therapy procedure (Loop Electro-Excision Procedure or Cold-Knife Conization) by 41.9% (95% CI: 27.7, 53.5) at end of study.
Silgards effekt hos kvinder fra 24 til 45 år blev vurderet i et klinisk, placebo-kontrolleret, dobbeltblindet, randomiseret fase III-studie (protokol 019, FUTURE III) med i alt 3.817 kvinder, som blev inkluderet og vaccineret uden forudgående screening for tilstedeværelsen af HPV-infektion.
The efficacy of Silgard in 24- through 45-year-old women was assessed in 1 placebo-controlled, double-blind, randomised Phase III clinical study (Protocol 019, FUTURE III) including a total of 3,817 women, who were enrolled and vaccinated without pre-screening for the presence of HPV infection.
Man har for HPV-vacciner ikke kunne identificere et minimums antistofniveau, som er associeret med
No minimum antibody level associated with protection has been identified for HPV vaccines.
Parenterale lægemidler skal inspiceres visuelt for tilstedeværelse af partikler og misfarvning forud for indgivelse.
Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration.
Dette gælder, uanset om det svækkede immunforsvar skyldes kraftig immunsuppressiv terapi, en genetisk defekt, eller andre årsager.
Individuals with impaired immune responsiveness, due to either the use of potent immunosuppressive therapy, a genetic defect, or other causes, may not respond to the vaccine.
Anti-HPV-respons i måned 7 hos 9-15-årige drenge antages at være sammenlignelige med anti-HPVrespons hos 16-26-årige mænd, for hvem effekten var blevet bestemt i fase III-studierne.
Anti-HPV responses at Month 7 among 9- to 15-year-old boys were non-inferior to anti-HPV responses in 16- to 26-year-old men for whom efficacy was established in the Phase III studies.
Ved rekruttering ligner denne population den generelle kvindelige befolkning for så vidt angår forekomst af HPV-infektion eller -sygdom.
This population approximates to the general population of women with respect to prevalence of HPV infection or disease at enrolment.
Disse kan omfatte åndedrætsbesvær, hvæsende åndedræt (bronkospasme), nældefeber og udslæt.
Allergic reactions that may include difficulty breathing, wheezing (bronchospasm), hives and rash have been reported.
Dyreforsøg med analoge papillomavira indikerer imidlertid, at L1 VLP-vaccinernes effekt medieres af udviklingen af humoralt
HPV only infects humans, but animal studies with analogous papillomaviruses suggest that the efficacy of LI VLP vaccines is mediated by the development of a humoral immune response.
Personer fra 9 år til og med 13 år Silgard kan indgives efter et program med 2 doser (0,5 ml ved måned 0 og 6) (se pkt.
Individuals 9 to and including 13 years of age Silgard can be administered according to a 2-dose schedule (0.5 ml at 0, 6 months) (see section 5.1).
Silgards effekt hos 16-26-årige mænd blev vurderet i et klinisk, placebo-kontrolleret, dobbeltblindet, randomiseret fase III-studie (Protokol 020) med i alt 4.055 mænd, der blev inkluderet og vaccineret uden forudgående screening for tilstedeværelse af HPV-infektion.
The efficacy of Silgard in 16- through 26-year-old men was assessed in 1 placebo-controlled, doubleblind, randomised Phase III clinical study (Protocol 020) including a total of 4,055 men who were enrolled and vaccinated without pre-screening for the presence of HPV infection.
B. BETINGELSER ELLER BEGRÆSNINGER VEDRØRENDE UDLEVERING OG
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY
Effekt hos kvinder, der var naive over for de(n) relevante vaccine-HPV-type(r)
Efficacy in women naïve to the relevant vaccine HPV type(s)
Hætteglasset skal omrystes grundigt umiddelbart før indgivelsen for at der
Thorough agitation immediately before administration is necessary to maintain
Hos kvinder, som var naive over for 14 almindeligt forekommende HPV-typer, og som havde en negativ Pap-test ved dag 1, havde Silgard ved studieafslutning reduceret incidensen af CIN 2/3 eller AIS forårsaget af vaccine- eller ikke-vaccine-HPV-typer med 42,7 % (95 % CI: 23,7; 57,3) og af kondylomer med 82,8 % (95 % CI:
Among women who were naïve to 14 common HPV types and had a negative Pap test at Day 1, administration of Silgard reduced the incidence of CIN 2/3 or AIS caused by vaccine- or non-vaccine HPV types by 42.7% (95% CI: 23.7, 57.3) and of genital warts by 82.8% (95% CI: 74.3, 88.8) at end of study.
Advarsler og forsigtighedsregler Fortæl det til lægen, apotekspersonalet eller sundhedspersonalet, hvis du eller dit barn:
Talk to your doctor, pharmacist or nurse before vaccination if you or your child
Silgard indeholder:
Do not receive Silgard if:
Tabel 8: Langtids-immunogenicitetsdata (per protokol population, piger og drenge i alderen 9-15 år) baseret på procentdele af seropositive forsøgspersoner, målt ved cLIA og IgG LIA (protokol 018) efter
Table 8: Long-term immunogenicity data (per-protocol population) based on percentage of seropositive subjects as measured by cLIA and IgG LIA (Protocol 018) at 10 years, in girls and boys
Montér kanylen ved at dreje den med uret indtil kanylen sidder godt og sikkert på sprøjten.
Attach the needle by twisting in a clockwise direction until the needle fits securely on the syringe.
I protokol 012 var effekten af Silgard med udgangspunkt i 6-måneders definitionen af persisterende infektion [prøver positive ved 2 eller flere følgende besøg efter hinanden med et interval på 6 måneder (±1 måned) eller længere] henholdsvis 98,7 % (95 % CI: 95,1; 99,8) for HPV 16, og 100 % (95 % CI: 93,2; 100) for HPV 18 efter en opfølgning på op til 4 år (gennemsnitligt 3,6 år).
In Protocol 012 the efficacy of Silgard against the 6 month definition of persistent infection [samples positive on two or more consecutive visits 6 months apart (±1 month) or longer] related to HPV 16 was 98.7 % (95% CI: 95.1, 99.8) and 100.0% (95% CI: 93.2, 100.0) for HPV 18 respectively, after a follow-up of up to 4 years (mean of 3.6 years).
I PPE-populationen blev der ikke set tilfælde af HPVsygdom (HPV-typer 6/11/16/18-relateret high-grade CIN) i op til ca. 12 år.
In the PPE population, no cases of HPV diseases (HPV types 6/11/16/18 related high grade CIN) were observed up to approximately 12 years.
4.1 refererer til high-grade anal intraepitelial neoplasi (AIN
The term "premalignant anal lesions" in section 4.1 corresponds to high-grade anal intraepithelial neoplasia (AIN 2/3).
Kvinder vaccineret med Silgard i 16-23-års-alderen i protokol 015-basisstudiet vil blive fulgt i op til 14 år i et udvidet studie.
Women vaccinated with Silgard at 16-23 years of age in Protocol 015 base study will be followed up to 14 years in an extension study.
Ved rekruttering ligner denne population den generelle mandlige befolkning med hensyn til prævalens af HPV-infektion ellersygdom.
This population approximates to the general population of men with respect to prevalence of HPV infection or disease at enrolment.
Silgards effekt imod HPV 6-, 11-, 16-, 18-relaterede kondylomer var 68,1 % (95 % CI: 48,8; 79,3).
The efficacy of Silgard against HPV 6-, 11-, 16-, 18-related external genital warts was 68.1% (95% CI: 48.8, 79.3).
Piger og drenge vaccineret med Silgard i 9-15-års-alderen i protokol 018-basisstudiet blev fulgt i et udvidet studie.
Girls and boys vaccinated with Silgard at 9-15 years of age in Protocol 018 base study were followed up in an extension study.
Vaccinen består af højtoprensede viruslignende partikler (VLP'er) af det vigtigste kapsidprotein L1 fra HPV-typerne 6, 11, 16 og 18.
Silgard is an adjuvanted non-infectious recombinant quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein of HPV types 6, 11, 16 and 18.
Adsorberet på amorft aluminium-hydroxyl-fosfat-sulfat (0,225 mg Al)
adsorbed on amorphous aluminium hydroxyphosphate sulphate (0.225 mg Al).
Effekt imod HPV 6-, 11-, 16-, 18-relateret VIN 2/3 var 73,3 % (95 % CI: 40,3; 89,4), imod HPV 6-, 11-, 16-, 18-relateret VaIN 2/3 var den 85,7 % (95 % CI: 37,6; 98,4) og imod HPV 6-, 11-, 16-, 18relaterede kondylomer 80,3 % (95 % CI: 73,9; 85,3) i de kombinerede protokoller ved
Efficacy against HPV 6-, 11-, 16-, 18-related VIN 2/3 was 73.3% (95% CI: 40.3, 89.4), against HPV 6-, 11-, 16-, 18-related VaIN 2/3 was 85.7% (95% CI: 37.6, 98.4), and against HPV 6-, 11-, 16-, 18-related genital warts was 80.3% (95% CI: 73.9, 85.3) in the combined protocols at end of study.
Human papillomavirusvaccine [type 6, 11, 16, 18] (rekombinant, adsorberet)
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed).
Effekt hos kvinder med og uden tidligere infektion eller sygdom, som skyldes HPV 6, 11, 16 eller 18
Efficacy in women with and without prior infection or disease due to HPV 6, 11, 16, or 18
Silgards effekt imod HPV 6-, 11-, 16-, 18-relaterede AIN 2/3 og HPV 16- eller 18-relaterede AIN 2/3 i MSM-substudiet var 54,2 % (95 % CI: 18,0; 75,3; 18/275 versus 39/276) og 57,5 % (95 % CI: -1,8;
The efficacy of Silgard against HPV 6-, 11-, 16-, 18-related AIN 2/3 and HPV 16- or 18-related AIN 2/3, in the MSM substudy, was 54.2% (95% CI: -18.0, 75.3; 18/275 versus 39/276) and 57.5% (95% CI: -1.8, 83.9; 8/275 versus 19/276 cases), respectively.
Effekten mod HPV 16- og 18-relateret persisterende infektion var 68,2 % (95 % CI: 17,9, 89,5; 6 versus 20 tilfælde [n = 832 fra studier med unge og voksne kvinder]) hos kvinder 16-45 år.
Efficacy was 68.2% (95% CI: 17.9, 89.5; 6 vs. 20 cases [n = 832 from studies in young and adult women combined]) against HPV 16- and 18-related persistent infection in women 16 to 45 years.
Effekt hos mænd med eller uden forudgående infektion eller sygdom på grund af HPV 6, 11, 16 eller
Efficacy in men with or without prior infection or disease due to HPV 6, 11, 16, or 18
Almindelige (forekommer hos mellem 1 og 10 ud af 100 patienter): Bivirkninger på injektionsstedet, herunder blåt mærke, kløe, smerte i arme eller ben.
Commonly (more than 1 in 100 patients), side effects found at the injection site include: bruising, itching, pain in extremity.